Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2012-05-31 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Exercise of Employee Options 11 pages 100.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities issued, their class, exercise prices, and expiry dates. The document references ASX (Australian Securities Exchange) rules and is a formal announcement of a securities issuance event. There is no financial performance data, management discussion, or audit information. The content fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and related capital changes.
2012-05-31 English
Pharmaxis Submits US New Drug Application for Bronchitol 2 pages 85.5KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing the submission of a New Drug Application (NDA) to the FDA for Bronchitol, a pharmaceutical product. It discusses clinical trial results, regulatory milestones, and future plans for marketing and reimbursement. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an announcement of a regulatory submission and product development milestone rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a regulatory announcement related to drug approval progress, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2012-05-20 English
Appendix 3B - Exercise of employee options 11 pages 100.5KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities issued, their class, exercise prices, and dates. The document references ASX rules and is structured as a formal announcement to the stock exchange regarding securities issuance and quotation. There are no financial statements, management discussion, or earnings data present. The content aligns with announcements related to share issues or capital changes rather than a full report or regulatory filing. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is substantial (15,000 characters), indicating it is not a brief notice but a detailed announcement of a capital change.
2012-05-20 English
Amended - Ceasing to be a substantial holder 4 pages 65.6KB
Major Shareholding Notification Classification · 95% confidence The document is titled 'Form 605 Notice of ceasing to be a substantial holder' under Corporations Law Section 671B. It details changes in substantial shareholdings and relevant interests in voting securities of Pharmaxis Limited, including dates, nature of changes, and number of securities affected. The document is a formal regulatory notice about shareholding changes, specifically ceasing to be a substantial holder, and includes detailed transaction data. It is not a financial report, earnings release, or management discussion. It is a regulatory filing notifying the market and regulators about changes in substantial shareholdings. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length and content support a high confidence in this classification.
2012-05-15 English
Ceasing to be a substantial holder 3 pages 63.0KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and is a 'Notice of ceasing to be a substantial holder' under Corporations Law Section 671B. It details changes in substantial shareholding interests, including dates, nature of changes, and securities affected. The content focuses on shareholding notifications and changes in ownership stakes rather than financial results, management changes, or regulatory compliance filings. This matches the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report, nor does it contain financial statements or management commentary. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2012-05-09 English
Appendix 3B Exercise of Employee Options 11 pages 100.6KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of securities issued, issue price, and dates. The document references ASX rules and is a formal announcement to the Australian Securities Exchange regarding new securities issued and their quotation. This type of document is a capital or financing update related to share issuance and securities listing, not a full financial report or earnings release. Therefore, it fits the category 'Capital/Financing Update' (CAP). The document length is substantial and contains detailed information about the securities issued, consistent with a capital update rather than a brief announcement or regulatory filing.
2012-05-01 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.